| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
FR054 targets phosphoglucomutase 3 (PGM3), a key enzyme in the hexosamine biosynthetic pathway (HBP). PGM3 catalyzes the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate, a critical step in the production of UDP-GlcNAc for protein glycosylation. By inhibiting PGM3, FR054 disrupts protein glycosylation and cellular metabolism, leading to anti-cancer effects.
|
|---|---|
| ln Vitro |
In breast cancer cells, FR054 (0.5–1 mM, 24-48 h) causes an early rise in proliferation, which is followed by a notable decrease in cell viability and an induction of cell display. FR054 inhibits PGM3 instead of having other unintended consequences [1]. (250 μM, 24 hours) therapy has a significant impact on MDA-MB-231 cells' levels of N- and O-glycosylation [1]. ROS-dependent cells and endoplasmic reticulum (ER) mesenchymal cells are induced in cells by FR054 [1].
In vitro, FR054 (0.5-1 mM, 24-48 h) induces an early proliferation arrest followed by a marked increase in cell death in breast cancer cells and induces apoptosis. In MDA-MB-231 cells, FR054 (250 μM, 24 h) effectively affects N- and O-glycosylation levels. It induces endoplasmic reticulum stress and ROS-dependent apoptotic cell death. The compound induces a dramatic decrease in cell proliferation and survival across various breast cancer cell lines. |
| ln Vivo |
FR054 (1000 mg/kg, intraperitoneal injection) inhibits cancer growth in MDA-MB-231 xenograft mice [1].
In vivo activity data for FR054 are not extensively reported. As a PGM3 inhibitor with anticancer activity, it would be expected to show efficacy in animal models of breast cancer. Further in vivo studies would be required to evaluate its therapeutic potential. |
| Enzyme Assay |
PGM3 enzymatic activity is measured using biochemical assays with recombinant PGM3 protein. The enzyme is incubated with its substrate (glucosamine-6-phosphate) in the presence of FR054 at varying concentrations. Product formation (glucosamine-1-phosphate) is measured, and IC50 values are calculated from dose-response curves. Typical assay conditions include incubation at 37°C in appropriate buffer systems.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: MDA-MB-231 cells. Tested Concentrations: 0.5-1 mM. Incubation Duration: 48 hrs (hours). Experimental Results: Viability was diminished and apoptosis was Dramatically increased compared to control clones. The cellular activity of FR054 is evaluated in breast cancer cell lines. Cells are treated with escalating concentrations of the compound (typically 0.5-1 mM for 24-48 h). Cell viability is measured using MTT or CellTiter-Glo assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining. Protein glycosylation levels are evaluated by Western blot using lectin-based detection. Endoplasmic reticulum stress and ROS production are measured using appropriate fluorescent probes. |
| Animal Protocol |
Animal/Disease Models: Mice are injected subcutaneously (sc) (sc) with MDA-MB-231 cells [1].
Doses: 1000 mg/kg. Route of Administration: IP, single or divided doses (500 mg/kg/dose twice (two times) daily). Experimental Results: Twice-daily dosing appeared to have greater in vivo antitumor efficacy compared with single dosing. In vivo efficacy of FR054 would typically be evaluated in xenograft mouse models of breast cancer. Tumor-bearing mice would be administered the compound, and tumor growth inhibition would be measured. Pharmacodynamic endpoints would include assessment of PGM3 inhibition and glycosylation levels in tumor tissues. |
| ADME/Pharmacokinetics |
FR054 has a molecular formula of C14H19NO8 and a molecular weight of 329.3 g/mol. Its SMILES is CC(=O)OC[C@H]1O[C@@H]2OC(C)=N[C@@H]2[C@@H](OC(C)=O)[C@@H]1OC(C)=O. It is soluble in H2O (50 mg/mL) and DMSO. Storage conditions are powder at -20°C for up to 2 years. The compound is a purified oil.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for FR054 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
FR054 is a hexosamine biosynthetic pathway enzyme PGM3 inhibitor with anticancer activity. It can be used in studies related to breast cancer. It has been cited in Nature Medicine for its top-tier quality. FR054 is a valuable tool for studying the role of the HBP and protein glycosylation in cancer biology.
|
| Molecular Formula |
C14H19NO8
|
|---|---|
| Molecular Weight |
329.31
|
| Exact Mass |
329.111
|
| Elemental Analysis |
C, 51.06; H, 5.82; N, 4.25; O, 38.87
|
| CAS # |
35954-65-5
|
| Related CAS # |
(6R)-FR054;10378-06-0
|
| PubChem CID |
9883925
|
| Appearance |
Colorless to light yellow Viscouse waxy semi-solid
|
| Density |
1.45±0.1 g/cm3(Predicted)
|
| Boiling Point |
416.7±45.0 °C(Predicted)
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC1=NC2C(C(C(OC2O1)COC(=O)C)OC(=O)C)OC(=O)C
|
| InChi Key |
WZFQZRLQMXZMJA-KSTCHIGDSA-N
|
| InChi Code |
InChI=1S/C14H19NO8/c1-6-15-11-13(22-9(4)18)12(21-8(3)17)10(5-19-7(2)16)23-14(11)20-6/h10-14H,5H2,1-4H3/t10-,11-,12-,13-,14+/m1/s1
|
| Chemical Name |
5H-Pyrano[3,2-d]oxazole-6,7-diol, 5-[(acetyloxy)methyl]-3a,6,7,7a-tetrahydro-2-methyl-, diacetate (ester), (3aR,5R,6S,7R,7aR)-
|
| Synonyms |
FR054; FR-054; FR 054
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~303.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0367 mL | 15.1833 mL | 30.3665 mL | |
| 5 mM | 0.6073 mL | 3.0367 mL | 6.0733 mL | |
| 10 mM | 0.3037 mL | 1.5183 mL | 3.0367 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
